Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319683 · ClinicalTrials.gov registry record · Phase 1
A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
A Phase 1 study, sponsored by Adherex Technologies.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00319683 is a Phase 1 study that was terminated before completion, run by Adherex Technologies.
The verdict
NCT00319683, a Phase 1 study, was terminated before completion, sponsored by Adherex Technologies.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
5-fluorouracil (5-FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5-FU in subjects with locally advanced, recurrent, or metastatic hepatocellular carcinoma.
Interventions
- DRUG ADH300004
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319683
The ClinicalTrials.gov registry entry for NCT00319683 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Adherex Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADH300004 is the first listed.
NCT00319683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00319683 about?
NCT00319683 is a clinical study titled "A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma". 5-fluorouracil (5-FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5-FU in subjects with locally advance...
What is the current status of trial NCT00319683?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00319683?
The interventions under investigation include: ADH300004 (DRUG).
Who is sponsoring clinical trial NCT00319683?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.